nodes	percent_of_prediction	percent_of_DWPC	metapath
Zalcitabine—SLC29A1—Fluorouracil—head and neck cancer	0.347	0.425	CbGbCtD
Zalcitabine—SLC22A7—Fluorouracil—head and neck cancer	0.131	0.16	CbGbCtD
Zalcitabine—SLC22A7—Docetaxel—head and neck cancer	0.0997	0.122	CbGbCtD
Zalcitabine—CYP2D6—Hydroxyurea—head and neck cancer	0.061	0.0747	CbGbCtD
Zalcitabine—CYP3A7—Docetaxel—head and neck cancer	0.0387	0.0474	CbGbCtD
Zalcitabine—CYP3A7-CYP3A51P—Docetaxel—head and neck cancer	0.0387	0.0474	CbGbCtD
Zalcitabine—CYP3A5—Docetaxel—head and neck cancer	0.029	0.0355	CbGbCtD
Zalcitabine—CYP2C9—Fluorouracil—head and neck cancer	0.0255	0.0312	CbGbCtD
Zalcitabine—CYP2D6—Vinblastine—head and neck cancer	0.0216	0.0264	CbGbCtD
Zalcitabine—CYP3A4—Vinblastine—head and neck cancer	0.0137	0.0168	CbGbCtD
Zalcitabine—CYP3A4—Docetaxel—head and neck cancer	0.0113	0.0139	CbGbCtD
Zalcitabine—Odynophagia—Docetaxel—head and neck cancer	0.00479	0.0351	CcSEcCtD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—XRCC3—head and neck cancer	0.00341	0.0781	CbGpPWpGaD
Zalcitabine—Common cold—Fluorouracil—head and neck cancer	0.00319	0.0233	CcSEcCtD
Zalcitabine—Gemcitabine—TYMS—head and neck cancer	0.003	1	CrCbGaD
Zalcitabine—Memory loss—Fluorouracil—head and neck cancer	0.00283	0.0207	CcSEcCtD
Zalcitabine—DCK—Pyrimidine metabolism—DPYD—head and neck cancer	0.00246	0.0563	CbGpPWpGaD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—DPYD—head and neck cancer	0.00227	0.0519	CbGpPWpGaD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—XRCC3—head and neck cancer	0.00194	0.0445	CbGpPWpGaD
Zalcitabine—Hypomagnesaemia—Hydroxyurea—head and neck cancer	0.00182	0.0133	CcSEcCtD
Zalcitabine—Neuritis—Vinblastine—head and neck cancer	0.0017	0.0124	CcSEcCtD
Zalcitabine—Oesophageal ulcer—Docetaxel—head and neck cancer	0.00165	0.0121	CcSEcCtD
Zalcitabine—Cardiomyopathy—Fluorouracil—head and neck cancer	0.00163	0.0119	CcSEcCtD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—SMUG1—head and neck cancer	0.00161	0.0369	CbGpPWpGaD
Zalcitabine—Blister—Hydroxyurea—head and neck cancer	0.0016	0.0117	CcSEcCtD
Zalcitabine—Bullous eruption—Docetaxel—head and neck cancer	0.00152	0.0111	CcSEcCtD
Zalcitabine—CYP3A43—Xenobiotics—CYP1A1—head and neck cancer	0.0015	0.0343	CbGpPWpGaD
Zalcitabine—Skin ulcer—Hydroxyurea—head and neck cancer	0.00148	0.0109	CcSEcCtD
Zalcitabine—Rectal haemorrhage—Vinblastine—head and neck cancer	0.0014	0.0103	CcSEcCtD
Zalcitabine—DCK—Pyrimidine metabolism—TYMS—head and neck cancer	0.0014	0.0321	CbGpPWpGaD
Zalcitabine—Cellulitis—Vinblastine—head and neck cancer	0.00139	0.0102	CcSEcCtD
Zalcitabine—Tenderness—Hydroxyurea—head and neck cancer	0.00132	0.0097	CcSEcCtD
Zalcitabine—Prurigo—Docetaxel—head and neck cancer	0.0013	0.00953	CcSEcCtD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—DPYD—head and neck cancer	0.00129	0.0296	CbGpPWpGaD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—TYMS—head and neck cancer	0.00129	0.0296	CbGpPWpGaD
Zalcitabine—Nail disorder—Fluorouracil—head and neck cancer	0.00128	0.0094	CcSEcCtD
Zalcitabine—Chest tightness—Docetaxel—head and neck cancer	0.00128	0.00938	CcSEcCtD
Zalcitabine—Hyperuricaemia—Hydroxyurea—head and neck cancer	0.00125	0.00913	CcSEcCtD
Zalcitabine—Ulcer—Hydroxyurea—head and neck cancer	0.00122	0.00895	CcSEcCtD
Zalcitabine—Creatinine increased—Hydroxyurea—head and neck cancer	0.00121	0.00889	CcSEcCtD
Zalcitabine—Heartburn—Fluorouracil—head and neck cancer	0.00121	0.00885	CcSEcCtD
Zalcitabine—Photophobia—Vinblastine—head and neck cancer	0.00119	0.00872	CcSEcCtD
Zalcitabine—Blood uric acid increased—Hydroxyurea—head and neck cancer	0.00118	0.00862	CcSEcCtD
Zalcitabine—Blister—Fluorouracil—head and neck cancer	0.00115	0.00845	CcSEcCtD
Zalcitabine—Skin exfoliation—Hydroxyurea—head and neck cancer	0.0011	0.00808	CcSEcCtD
Zalcitabine—Blood urea increased—Hydroxyurea—head and neck cancer	0.00109	0.00799	CcSEcCtD
Zalcitabine—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.00105	0.0077	CcSEcCtD
Zalcitabine—Deafness—Vinblastine—head and neck cancer	0.00103	0.00753	CcSEcCtD
Zalcitabine—DCK—Purine metabolism—GPX1—head and neck cancer	0.00103	0.0236	CbGpPWpGaD
Zalcitabine—Haemorrhoids—Docetaxel—head and neck cancer	0.00102	0.00748	CcSEcCtD
Zalcitabine—Eye irritation—Fluorouracil—head and neck cancer	0.000974	0.00714	CcSEcCtD
Zalcitabine—Speech disorder—Fluorouracil—head and neck cancer	0.000967	0.00709	CcSEcCtD
Zalcitabine—DCK—Nucleotide metabolism—DPYD—head and neck cancer	0.000958	0.0219	CbGpPWpGaD
Zalcitabine—Tenderness—Fluorouracil—head and neck cancer	0.000954	0.00698	CcSEcCtD
Zalcitabine—Nail disorder—Docetaxel—head and neck cancer	0.000926	0.00678	CcSEcCtD
Zalcitabine—Parosmia—Docetaxel—head and neck cancer	0.000926	0.00678	CcSEcCtD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—SMUG1—head and neck cancer	0.000919	0.021	CbGpPWpGaD
Zalcitabine—Cellulitis—Fluorouracil—head and neck cancer	0.000915	0.0067	CcSEcCtD
Zalcitabine—Renal failure acute—Hydroxyurea—head and neck cancer	0.000909	0.00666	CcSEcCtD
Zalcitabine—Ulcer—Fluorouracil—head and neck cancer	0.00088	0.00644	CcSEcCtD
Zalcitabine—Dermatitis bullous—Hydroxyurea—head and neck cancer	0.000878	0.00643	CcSEcCtD
Zalcitabine—Heartburn—Docetaxel—head and neck cancer	0.000873	0.00639	CcSEcCtD
Zalcitabine—Neuralgia—Docetaxel—head and neck cancer	0.000864	0.00633	CcSEcCtD
Zalcitabine—Inflammation—Fluorouracil—head and neck cancer	0.000858	0.00628	CcSEcCtD
Zalcitabine—Throat sore—Docetaxel—head and neck cancer	0.000833	0.0061	CcSEcCtD
Zalcitabine—Oropharyngeal discomfort—Docetaxel—head and neck cancer	0.000826	0.00605	CcSEcCtD
Zalcitabine—Neuritis—Docetaxel—head and neck cancer	0.000804	0.00589	CcSEcCtD
Zalcitabine—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.000786	0.00576	CcSEcCtD
Zalcitabine—Rash erythematous—Docetaxel—head and neck cancer	0.000784	0.00574	CcSEcCtD
Zalcitabine—Photophobia—Fluorouracil—head and neck cancer	0.000781	0.00572	CcSEcCtD
Zalcitabine—Oesophagitis—Fluorouracil—head and neck cancer	0.00076	0.00557	CcSEcCtD
Zalcitabine—Rash maculo-papular—Fluorouracil—head and neck cancer	0.000756	0.00554	CcSEcCtD
Zalcitabine—Rhinorrhoea—Docetaxel—head and neck cancer	0.000741	0.00543	CcSEcCtD
Zalcitabine—Ageusia—Docetaxel—head and neck cancer	0.000741	0.00543	CcSEcCtD
Zalcitabine—Rigors—Docetaxel—head and neck cancer	0.000736	0.00539	CcSEcCtD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—TYMS—head and neck cancer	0.000735	0.0168	CbGpPWpGaD
Zalcitabine—Euphoric mood—Fluorouracil—head and neck cancer	0.000715	0.00524	CcSEcCtD
Zalcitabine—Pancreatitis—Hydroxyurea—head and neck cancer	0.000711	0.00521	CcSEcCtD
Zalcitabine—Depression—Vinblastine—head and neck cancer	0.000707	0.00518	CcSEcCtD
Zalcitabine—Eye irritation—Docetaxel—head and neck cancer	0.000703	0.00515	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Vinblastine—head and neck cancer	0.000695	0.00509	CcSEcCtD
Zalcitabine—Swelling—Fluorouracil—head and neck cancer	0.000685	0.00501	CcSEcCtD
Zalcitabine—Chest discomfort—Docetaxel—head and neck cancer	0.000679	0.00497	CcSEcCtD
Zalcitabine—Dysuria—Hydroxyurea—head and neck cancer	0.000678	0.00497	CcSEcCtD
Zalcitabine—Neutropenia—Hydroxyurea—head and neck cancer	0.000678	0.00497	CcSEcCtD
Zalcitabine—Hyperbilirubinaemia—Docetaxel—head and neck cancer	0.00066	0.00484	CcSEcCtD
Zalcitabine—Oropharyngeal pain—Docetaxel—head and neck cancer	0.00066	0.00484	CcSEcCtD
Zalcitabine—Amnesia—Fluorouracil—head and neck cancer	0.000643	0.00471	CcSEcCtD
Zalcitabine—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.000639	0.0146	CbGpPWpGaD
Zalcitabine—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000634	0.00464	CcSEcCtD
Zalcitabine—Dermatitis bullous—Fluorouracil—head and neck cancer	0.000632	0.00463	CcSEcCtD
Zalcitabine—Pharyngitis—Vinblastine—head and neck cancer	0.000632	0.00463	CcSEcCtD
Zalcitabine—Hearing impaired—Docetaxel—head and neck cancer	0.000631	0.00462	CcSEcCtD
Zalcitabine—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000621	0.0142	CbGpPWpGaD
Zalcitabine—Inflammation—Docetaxel—head and neck cancer	0.000619	0.00453	CcSEcCtD
Zalcitabine—Cardiac failure—Fluorouracil—head and neck cancer	0.000619	0.00453	CcSEcCtD
Zalcitabine—CYP3A43—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000613	0.014	CbGpPWpGaD
Zalcitabine—Osteoarthritis—Fluorouracil—head and neck cancer	0.000604	0.00442	CcSEcCtD
Zalcitabine—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000604	0.00442	CcSEcCtD
Zalcitabine—CYP3A7—Xenobiotics—CYP1A1—head and neck cancer	0.000603	0.0138	CbGpPWpGaD
Zalcitabine—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.000601	0.0044	CcSEcCtD
Zalcitabine—Hepatocellular injury—Docetaxel—head and neck cancer	0.000601	0.0044	CcSEcCtD
Zalcitabine—Influenza like illness—Docetaxel—head and neck cancer	0.000583	0.00427	CcSEcCtD
Zalcitabine—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.000582	0.0133	CbGpPWpGaD
Zalcitabine—Hallucination—Hydroxyurea—head and neck cancer	0.000578	0.00423	CcSEcCtD
Zalcitabine—Colitis—Docetaxel—head and neck cancer	0.000577	0.00422	CcSEcCtD
Zalcitabine—Candida infection—Docetaxel—head and neck cancer	0.000573	0.0042	CcSEcCtD
Zalcitabine—Skin exfoliation—Docetaxel—head and neck cancer	0.000573	0.0042	CcSEcCtD
Zalcitabine—CYP3A43—Biological oxidations—NAT2—head and neck cancer	0.000571	0.0131	CbGpPWpGaD
Zalcitabine—Ataxia—Fluorouracil—head and neck cancer	0.000568	0.00416	CcSEcCtD
Zalcitabine—CYP3A43—Metapathway biotransformation—NAT2—head and neck cancer	0.000564	0.0129	CbGpPWpGaD
Zalcitabine—Alopecia—Vinblastine—head and neck cancer	0.000562	0.00412	CcSEcCtD
Zalcitabine—Dry skin—Fluorouracil—head and neck cancer	0.000554	0.00405	CcSEcCtD
Zalcitabine—Oesophagitis—Docetaxel—head and neck cancer	0.000549	0.00402	CcSEcCtD
Zalcitabine—DCK—Nucleotide metabolism—TYMS—head and neck cancer	0.000546	0.0125	CbGpPWpGaD
Zalcitabine—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00054	0.00396	CcSEcCtD
Zalcitabine—Muscular weakness—Fluorouracil—head and neck cancer	0.000533	0.0039	CcSEcCtD
Zalcitabine—Dysphagia—Fluorouracil—head and neck cancer	0.000522	0.00382	CcSEcCtD
Zalcitabine—Chills—Hydroxyurea—head and neck cancer	0.000521	0.00381	CcSEcCtD
Zalcitabine—Eosinophilia—Fluorouracil—head and neck cancer	0.000517	0.00379	CcSEcCtD
Zalcitabine—DCK—Nucleotide metabolism—GPX1—head and neck cancer	0.000517	0.0118	CbGpPWpGaD
Zalcitabine—Ill-defined disorder—Vinblastine—head and neck cancer	0.000514	0.00377	CcSEcCtD
Zalcitabine—Alopecia—Hydroxyurea—head and neck cancer	0.000513	0.00376	CcSEcCtD
Zalcitabine—Anaemia—Vinblastine—head and neck cancer	0.000512	0.00375	CcSEcCtD
Zalcitabine—CYP3A43—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000504	0.0115	CbGpPWpGaD
Zalcitabine—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000501	0.00367	CcSEcCtD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—TYMS—head and neck cancer	0.0005	0.0115	CbGpPWpGaD
Zalcitabine—Malaise—Vinblastine—head and neck cancer	0.0005	0.00366	CcSEcCtD
Zalcitabine—Vertigo—Vinblastine—head and neck cancer	0.000498	0.00365	CcSEcCtD
Zalcitabine—Leukopenia—Vinblastine—head and neck cancer	0.000496	0.00363	CcSEcCtD
Zalcitabine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.000495	0.0113	CbGpPWpGaD
Zalcitabine—Swelling—Docetaxel—head and neck cancer	0.000494	0.00362	CcSEcCtD
Zalcitabine—Deafness—Docetaxel—head and neck cancer	0.000487	0.00357	CcSEcCtD
Zalcitabine—Convulsion—Vinblastine—head and neck cancer	0.00048	0.00352	CcSEcCtD
Zalcitabine—Hypertension—Vinblastine—head and neck cancer	0.000478	0.0035	CcSEcCtD
Zalcitabine—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000476	0.00349	CcSEcCtD
Zalcitabine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000469	0.00343	CcSEcCtD
Zalcitabine—Anaemia—Hydroxyurea—head and neck cancer	0.000467	0.00342	CcSEcCtD
Zalcitabine—Discomfort—Vinblastine—head and neck cancer	0.000466	0.00341	CcSEcCtD
Zalcitabine—Hot flush—Docetaxel—head and neck cancer	0.000466	0.00341	CcSEcCtD
Zalcitabine—Menopausal symptoms—Docetaxel—head and neck cancer	0.000462	0.00338	CcSEcCtD
Zalcitabine—Atrial fibrillation—Docetaxel—head and neck cancer	0.00046	0.00337	CcSEcCtD
Zalcitabine—SLC29A2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.00046	0.0105	CbGpPWpGaD
Zalcitabine—Renal impairment—Docetaxel—head and neck cancer	0.000458	0.00335	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000456	0.00334	CcSEcCtD
Zalcitabine—Dermatitis bullous—Docetaxel—head and neck cancer	0.000456	0.00334	CcSEcCtD
Zalcitabine—Malaise—Hydroxyurea—head and neck cancer	0.000456	0.00334	CcSEcCtD
Zalcitabine—Leukopenia—Hydroxyurea—head and neck cancer	0.000452	0.00331	CcSEcCtD
Zalcitabine—Cardiac failure—Docetaxel—head and neck cancer	0.000447	0.00327	CcSEcCtD
Zalcitabine—Thrombocytopenia—Vinblastine—head and neck cancer	0.000443	0.00324	CcSEcCtD
Zalcitabine—Epistaxis—Fluorouracil—head and neck cancer	0.000439	0.00322	CcSEcCtD
Zalcitabine—Convulsion—Hydroxyurea—head and neck cancer	0.000438	0.00321	CcSEcCtD
Zalcitabine—Hyponatraemia—Docetaxel—head and neck cancer	0.000438	0.00321	CcSEcCtD
Zalcitabine—Sinusitis—Fluorouracil—head and neck cancer	0.000437	0.0032	CcSEcCtD
Zalcitabine—Pain in extremity—Docetaxel—head and neck cancer	0.000436	0.00319	CcSEcCtD
Zalcitabine—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000436	0.00319	CcSEcCtD
Zalcitabine—CYP3A5—Xenobiotics—CYP1A1—head and neck cancer	0.000436	0.00998	CbGpPWpGaD
Zalcitabine—Anorexia—Vinblastine—head and neck cancer	0.000431	0.00316	CcSEcCtD
Zalcitabine—Migraine—Docetaxel—head and neck cancer	0.000429	0.00314	CcSEcCtD
Zalcitabine—SLC29A1—Fluoropyrimidine Activity—TP53—head and neck cancer	0.000428	0.00981	CbGpPWpGaD
Zalcitabine—Discomfort—Hydroxyurea—head and neck cancer	0.000425	0.00311	CcSEcCtD
Zalcitabine—CYP3A5—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000419	0.0096	CbGpPWpGaD
Zalcitabine—Rhinitis—Fluorouracil—head and neck cancer	0.000419	0.00307	CcSEcCtD
Zalcitabine—Pharyngitis—Fluorouracil—head and neck cancer	0.000415	0.00304	CcSEcCtD
Zalcitabine—Oedema—Hydroxyurea—head and neck cancer	0.000412	0.00302	CcSEcCtD
Zalcitabine—Ataxia—Docetaxel—head and neck cancer	0.00041	0.003	CcSEcCtD
Zalcitabine—Infection—Hydroxyurea—head and neck cancer	0.00041	0.003	CcSEcCtD
Zalcitabine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000404	0.00296	CcSEcCtD
Zalcitabine—Skin disorder—Hydroxyurea—head and neck cancer	0.000401	0.00293	CcSEcCtD
Zalcitabine—Dry skin—Docetaxel—head and neck cancer	0.0004	0.00293	CcSEcCtD
Zalcitabine—Abdominal pain upper—Docetaxel—head and neck cancer	0.000398	0.00292	CcSEcCtD
Zalcitabine—Anorexia—Hydroxyurea—head and neck cancer	0.000393	0.00288	CcSEcCtD
Zalcitabine—Decreased appetite—Vinblastine—head and neck cancer	0.000393	0.00288	CcSEcCtD
Zalcitabine—Cramp muscle—Docetaxel—head and neck cancer	0.000393	0.00288	CcSEcCtD
Zalcitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000392	0.00899	CbGpPWpGaD
Zalcitabine—Nasopharyngitis—Docetaxel—head and neck cancer	0.00039	0.00286	CcSEcCtD
Zalcitabine—Pain—Vinblastine—head and neck cancer	0.000387	0.00283	CcSEcCtD
Zalcitabine—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.000384	0.00879	CbGpPWpGaD
Zalcitabine—Dysphagia—Docetaxel—head and neck cancer	0.000377	0.00276	CcSEcCtD
Zalcitabine—Arrhythmia—Fluorouracil—head and neck cancer	0.000373	0.00273	CcSEcCtD
Zalcitabine—Feeling abnormal—Vinblastine—head and neck cancer	0.000373	0.00273	CcSEcCtD
Zalcitabine—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.00037	0.00848	CbGpPWpGaD
Zalcitabine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00037	0.00271	CcSEcCtD
Zalcitabine—Alopecia—Fluorouracil—head and neck cancer	0.000369	0.0027	CcSEcCtD
Zalcitabine—Dyspnoea—Hydroxyurea—head and neck cancer	0.000368	0.00269	CcSEcCtD
Zalcitabine—Somnolence—Hydroxyurea—head and neck cancer	0.000367	0.00269	CcSEcCtD
Zalcitabine—Dyspepsia—Hydroxyurea—head and neck cancer	0.000363	0.00266	CcSEcCtD
Zalcitabine—Decreased appetite—Hydroxyurea—head and neck cancer	0.000358	0.00263	CcSEcCtD
Zalcitabine—Abdominal pain—Vinblastine—head and neck cancer	0.000357	0.00262	CcSEcCtD
Zalcitabine—Fatigue—Hydroxyurea—head and neck cancer	0.000356	0.0026	CcSEcCtD
Zalcitabine—Pain—Hydroxyurea—head and neck cancer	0.000353	0.00258	CcSEcCtD
Zalcitabine—Neutropenia—Docetaxel—head and neck cancer	0.000352	0.00258	CcSEcCtD
Zalcitabine—Vision blurred—Fluorouracil—head and neck cancer	0.000343	0.00251	CcSEcCtD
Zalcitabine—Weight decreased—Docetaxel—head and neck cancer	0.000341	0.0025	CcSEcCtD
Zalcitabine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00034	0.00249	CcSEcCtD
Zalcitabine—Anaemia—Fluorouracil—head and neck cancer	0.000336	0.00246	CcSEcCtD
Zalcitabine—Hypersensitivity—Vinblastine—head and neck cancer	0.000333	0.00244	CcSEcCtD
Zalcitabine—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000329	0.00241	CcSEcCtD
Zalcitabine—Jaundice—Docetaxel—head and neck cancer	0.000327	0.0024	CcSEcCtD
Zalcitabine—Body temperature increased—Hydroxyurea—head and neck cancer	0.000326	0.00239	CcSEcCtD
Zalcitabine—Leukopenia—Fluorouracil—head and neck cancer	0.000326	0.00238	CcSEcCtD
Zalcitabine—Asthenia—Vinblastine—head and neck cancer	0.000324	0.00238	CcSEcCtD
Zalcitabine—SLC29A1—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000319	0.0073	CbGpPWpGaD
Zalcitabine—Epistaxis—Docetaxel—head and neck cancer	0.000317	0.00232	CcSEcCtD
Zalcitabine—Convulsion—Fluorouracil—head and neck cancer	0.000315	0.00231	CcSEcCtD
Zalcitabine—CYP2D6—Xenobiotics—CYP1A1—head and neck cancer	0.00031	0.0071	CbGpPWpGaD
Zalcitabine—Myalgia—Fluorouracil—head and neck cancer	0.00031	0.00227	CcSEcCtD
Zalcitabine—Diarrhoea—Vinblastine—head and neck cancer	0.000309	0.00227	CcSEcCtD
Zalcitabine—CYP2C9—Xenobiotics—CYP1A1—head and neck cancer	0.000307	0.00703	CbGpPWpGaD
Zalcitabine—Discomfort—Fluorouracil—head and neck cancer	0.000306	0.00224	CcSEcCtD
Zalcitabine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000304	0.00223	CcSEcCtD
Zalcitabine—Rhinitis—Docetaxel—head and neck cancer	0.000302	0.00221	CcSEcCtD
Zalcitabine—Hepatitis—Docetaxel—head and neck cancer	0.000302	0.00221	CcSEcCtD
Zalcitabine—Confusional state—Fluorouracil—head and neck cancer	0.000299	0.00219	CcSEcCtD
Zalcitabine—Pharyngitis—Docetaxel—head and neck cancer	0.000299	0.00219	CcSEcCtD
Zalcitabine—Dizziness—Vinblastine—head and neck cancer	0.000299	0.00219	CcSEcCtD
Zalcitabine—CYP2D6—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000298	0.00682	CbGpPWpGaD
Zalcitabine—Oedema—Fluorouracil—head and neck cancer	0.000297	0.00217	CcSEcCtD
Zalcitabine—Asthenia—Hydroxyurea—head and neck cancer	0.000296	0.00217	CcSEcCtD
Zalcitabine—CYP2C9—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000295	0.00677	CbGpPWpGaD
Zalcitabine—Infection—Fluorouracil—head and neck cancer	0.000295	0.00216	CcSEcCtD
Zalcitabine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000291	0.00213	CcSEcCtD
Zalcitabine—Visual impairment—Docetaxel—head and neck cancer	0.000291	0.00213	CcSEcCtD
Zalcitabine—Tachycardia—Fluorouracil—head and neck cancer	0.00029	0.00212	CcSEcCtD
Zalcitabine—Vomiting—Vinblastine—head and neck cancer	0.000288	0.00211	CcSEcCtD
Zalcitabine—Headache—Vinblastine—head and neck cancer	0.000283	0.00207	CcSEcCtD
Zalcitabine—Anorexia—Fluorouracil—head and neck cancer	0.000283	0.00207	CcSEcCtD
Zalcitabine—CYP3A43—Biological oxidations—GSTM1—head and neck cancer	0.000282	0.00646	CbGpPWpGaD
Zalcitabine—Diarrhoea—Hydroxyurea—head and neck cancer	0.000282	0.00207	CcSEcCtD
Zalcitabine—Eye disorder—Docetaxel—head and neck cancer	0.000282	0.00206	CcSEcCtD
Zalcitabine—Flushing—Docetaxel—head and neck cancer	0.00028	0.00205	CcSEcCtD
Zalcitabine—CYP3A43—Metapathway biotransformation—GSTM1—head and neck cancer	0.000278	0.00638	CbGpPWpGaD
Zalcitabine—Dizziness—Hydroxyurea—head and neck cancer	0.000273	0.002	CcSEcCtD
Zalcitabine—Chills—Docetaxel—head and neck cancer	0.000271	0.00198	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00027	0.00198	CcSEcCtD
Zalcitabine—Arrhythmia—Docetaxel—head and neck cancer	0.000269	0.00197	CcSEcCtD
Zalcitabine—Insomnia—Fluorouracil—head and neck cancer	0.000268	0.00197	CcSEcCtD
Zalcitabine—CYP3A43—Biological oxidations—CYP1A1—head and neck cancer	0.000268	0.00613	CbGpPWpGaD
Zalcitabine—Alopecia—Docetaxel—head and neck cancer	0.000266	0.00195	CcSEcCtD
Zalcitabine—Dyspnoea—Fluorouracil—head and neck cancer	0.000265	0.00194	CcSEcCtD
Zalcitabine—Somnolence—Fluorouracil—head and neck cancer	0.000264	0.00193	CcSEcCtD
Zalcitabine—CYP3A43—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000264	0.00604	CbGpPWpGaD
Zalcitabine—Vomiting—Hydroxyurea—head and neck cancer	0.000262	0.00192	CcSEcCtD
Zalcitabine—Dyspepsia—Fluorouracil—head and neck cancer	0.000261	0.00191	CcSEcCtD
Zalcitabine—Rash—Hydroxyurea—head and neck cancer	0.00026	0.0019	CcSEcCtD
Zalcitabine—Dermatitis—Hydroxyurea—head and neck cancer	0.00026	0.0019	CcSEcCtD
Zalcitabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000259	0.00593	CbGpPWpGaD
Zalcitabine—Headache—Hydroxyurea—head and neck cancer	0.000258	0.00189	CcSEcCtD
Zalcitabine—Decreased appetite—Fluorouracil—head and neck cancer	0.000258	0.00189	CcSEcCtD
Zalcitabine—Dysgeusia—Docetaxel—head and neck cancer	0.000257	0.00188	CcSEcCtD
Zalcitabine—Back pain—Docetaxel—head and neck cancer	0.000254	0.00186	CcSEcCtD
Zalcitabine—Pain—Fluorouracil—head and neck cancer	0.000254	0.00186	CcSEcCtD
Zalcitabine—Muscle spasms—Docetaxel—head and neck cancer	0.000252	0.00185	CcSEcCtD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—head and neck cancer	0.000252	0.00577	CbGpPWpGaD
Zalcitabine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.00025	0.00573	CbGpPWpGaD
Zalcitabine—CYP3A7—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000247	0.00566	CbGpPWpGaD
Zalcitabine—Feeling abnormal—Fluorouracil—head and neck cancer	0.000245	0.00179	CcSEcCtD
Zalcitabine—SLC22A7—Fluoropyrimidine Activity—TP53—head and neck cancer	0.000244	0.00559	CbGpPWpGaD
Zalcitabine—Anaemia—Docetaxel—head and neck cancer	0.000243	0.00178	CcSEcCtD
Zalcitabine—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000242	0.00555	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—UROD—head and neck cancer	0.000239	0.00547	CbGpPWpGaD
Zalcitabine—Urticaria—Fluorouracil—head and neck cancer	0.000236	0.00173	CcSEcCtD
Zalcitabine—Syncope—Docetaxel—head and neck cancer	0.000235	0.00172	CcSEcCtD
Zalcitabine—CYP3A43—Metabolism—UROD—head and neck cancer	0.000235	0.00539	CbGpPWpGaD
Zalcitabine—Leukopenia—Docetaxel—head and neck cancer	0.000235	0.00172	CcSEcCtD
Zalcitabine—Body temperature increased—Fluorouracil—head and neck cancer	0.000235	0.00172	CcSEcCtD
Zalcitabine—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.000232	0.00532	CbGpPWpGaD
Zalcitabine—Palpitations—Docetaxel—head and neck cancer	0.000232	0.0017	CcSEcCtD
Zalcitabine—Loss of consciousness—Docetaxel—head and neck cancer	0.000231	0.00169	CcSEcCtD
Zalcitabine—CYP3A7—Biological oxidations—NAT2—head and neck cancer	0.00023	0.00527	CbGpPWpGaD
Zalcitabine—CYP2D6—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.00023	0.00527	CbGpPWpGaD
Zalcitabine—Cough—Docetaxel—head and neck cancer	0.000229	0.00168	CcSEcCtD
Zalcitabine—Convulsion—Docetaxel—head and neck cancer	0.000227	0.00167	CcSEcCtD
Zalcitabine—CYP3A7—Metapathway biotransformation—NAT2—head and neck cancer	0.000227	0.0052	CbGpPWpGaD
Zalcitabine—Hypertension—Docetaxel—head and neck cancer	0.000227	0.00166	CcSEcCtD
Zalcitabine—Myalgia—Docetaxel—head and neck cancer	0.000223	0.00164	CcSEcCtD
Zalcitabine—Arthralgia—Docetaxel—head and neck cancer	0.000223	0.00164	CcSEcCtD
Zalcitabine—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.00022	0.00505	CbGpPWpGaD
Zalcitabine—Hypersensitivity—Fluorouracil—head and neck cancer	0.000219	0.0016	CcSEcCtD
Zalcitabine—Dry mouth—Docetaxel—head and neck cancer	0.000219	0.0016	CcSEcCtD
Zalcitabine—Confusional state—Docetaxel—head and neck cancer	0.000216	0.00158	CcSEcCtD
Zalcitabine—Oedema—Docetaxel—head and neck cancer	0.000214	0.00157	CcSEcCtD
Zalcitabine—Infection—Docetaxel—head and neck cancer	0.000213	0.00156	CcSEcCtD
Zalcitabine—Shock—Docetaxel—head and neck cancer	0.000211	0.00154	CcSEcCtD
Zalcitabine—Pruritus—Fluorouracil—head and neck cancer	0.00021	0.00154	CcSEcCtD
Zalcitabine—Thrombocytopenia—Docetaxel—head and neck cancer	0.00021	0.00154	CcSEcCtD
Zalcitabine—Tachycardia—Docetaxel—head and neck cancer	0.000209	0.00153	CcSEcCtD
Zalcitabine—Skin disorder—Docetaxel—head and neck cancer	0.000208	0.00152	CcSEcCtD
Zalcitabine—Anorexia—Docetaxel—head and neck cancer	0.000204	0.0015	CcSEcCtD
Zalcitabine—Diarrhoea—Fluorouracil—head and neck cancer	0.000203	0.00149	CcSEcCtD
Zalcitabine—CYP3A7—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000203	0.00465	CbGpPWpGaD
Zalcitabine—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.000203	0.00464	CbGpPWpGaD
Zalcitabine—Dizziness—Fluorouracil—head and neck cancer	0.000196	0.00144	CcSEcCtD
Zalcitabine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000195	0.00143	CcSEcCtD
Zalcitabine—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000195	0.00446	CbGpPWpGaD
Zalcitabine—Insomnia—Docetaxel—head and neck cancer	0.000194	0.00142	CcSEcCtD
Zalcitabine—Dyspnoea—Docetaxel—head and neck cancer	0.000191	0.0014	CcSEcCtD
Zalcitabine—Somnolence—Docetaxel—head and neck cancer	0.00019	0.0014	CcSEcCtD
Zalcitabine—Vomiting—Fluorouracil—head and neck cancer	0.000189	0.00138	CcSEcCtD
Zalcitabine—Dyspepsia—Docetaxel—head and neck cancer	0.000189	0.00138	CcSEcCtD
Zalcitabine—Rash—Fluorouracil—head and neck cancer	0.000187	0.00137	CcSEcCtD
Zalcitabine—Dermatitis—Fluorouracil—head and neck cancer	0.000187	0.00137	CcSEcCtD
Zalcitabine—Decreased appetite—Docetaxel—head and neck cancer	0.000186	0.00136	CcSEcCtD
Zalcitabine—Headache—Fluorouracil—head and neck cancer	0.000186	0.00136	CcSEcCtD
Zalcitabine—Fatigue—Docetaxel—head and neck cancer	0.000185	0.00135	CcSEcCtD
Zalcitabine—Pain—Docetaxel—head and neck cancer	0.000183	0.00134	CcSEcCtD
Zalcitabine—SLC22A7—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000181	0.00416	CbGpPWpGaD
Zalcitabine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000181	0.00414	CbGpPWpGaD
Zalcitabine—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000178	0.00409	CbGpPWpGaD
Zalcitabine—Feeling abnormal—Docetaxel—head and neck cancer	0.000177	0.00129	CcSEcCtD
Zalcitabine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000175	0.00128	CcSEcCtD
Zalcitabine—Abdominal pain—Docetaxel—head and neck cancer	0.000169	0.00124	CcSEcCtD
Zalcitabine—Body temperature increased—Docetaxel—head and neck cancer	0.000169	0.00124	CcSEcCtD
Zalcitabine—CYP3A5—Biological oxidations—NAT2—head and neck cancer	0.000166	0.00381	CbGpPWpGaD
Zalcitabine—DCK—Retinoblastoma (RB) in Cancer—TP53—head and neck cancer	0.000166	0.0038	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—NAT2—head and neck cancer	0.000164	0.00376	CbGpPWpGaD
Zalcitabine—Hypersensitivity—Docetaxel—head and neck cancer	0.000158	0.00116	CcSEcCtD
Zalcitabine—Asthenia—Docetaxel—head and neck cancer	0.000154	0.00113	CcSEcCtD
Zalcitabine—Pruritus—Docetaxel—head and neck cancer	0.000152	0.00111	CcSEcCtD
Zalcitabine—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000149	0.00341	CbGpPWpGaD
Zalcitabine—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000148	0.00338	CbGpPWpGaD
Zalcitabine—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000147	0.00336	CbGpPWpGaD
Zalcitabine—Diarrhoea—Docetaxel—head and neck cancer	0.000147	0.00107	CcSEcCtD
Zalcitabine—Dizziness—Docetaxel—head and neck cancer	0.000142	0.00104	CcSEcCtD
Zalcitabine—Vomiting—Docetaxel—head and neck cancer	0.000136	0.000998	CcSEcCtD
Zalcitabine—Rash—Docetaxel—head and neck cancer	0.000135	0.000989	CcSEcCtD
Zalcitabine—Dermatitis—Docetaxel—head and neck cancer	0.000135	0.000989	CcSEcCtD
Zalcitabine—Headache—Docetaxel—head and neck cancer	0.000134	0.000983	CcSEcCtD
Zalcitabine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000129	0.00295	CbGpPWpGaD
Zalcitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000128	0.00292	CbGpPWpGaD
Zalcitabine—SLC22A6—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000127	0.00292	CbGpPWpGaD
Zalcitabine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000127	0.00291	CbGpPWpGaD
Zalcitabine—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000126	0.00288	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—NAT2—head and neck cancer	0.000118	0.00271	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.000117	0.00269	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—NAT2—head and neck cancer	0.000117	0.00267	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.000116	0.00265	CbGpPWpGaD
Zalcitabine—CYP3A7—Biological oxidations—GSTM1—head and neck cancer	0.000114	0.0026	CbGpPWpGaD
Zalcitabine—CYP3A7—Metapathway biotransformation—GSTM1—head and neck cancer	0.000112	0.00257	CbGpPWpGaD
Zalcitabine—CYP3A7—Biological oxidations—CYP1A1—head and neck cancer	0.000108	0.00247	CbGpPWpGaD
Zalcitabine—CYP3A7—Metapathway biotransformation—CYP1A1—head and neck cancer	0.000106	0.00243	CbGpPWpGaD
Zalcitabine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000104	0.00239	CbGpPWpGaD
Zalcitabine—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	0.000104	0.00238	CbGpPWpGaD
Zalcitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000103	0.00237	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—NAT2—head and neck cancer	9.92e-05	0.00227	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—NAT2—head and neck cancer	9.77e-05	0.00224	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—UROD—head and neck cancer	9.48e-05	0.00217	CbGpPWpGaD
Zalcitabine—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	8.77e-05	0.00201	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—DPYD—head and neck cancer	8.7e-05	0.00199	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—DPYD—head and neck cancer	8.57e-05	0.00196	CbGpPWpGaD
Zalcitabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	8.41e-05	0.00193	CbGpPWpGaD
Zalcitabine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	8.3e-05	0.0019	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—YAP1—head and neck cancer	8.26e-05	0.00189	CbGpPWpGaD
Zalcitabine—CYP3A5—Biological oxidations—GSTM1—head and neck cancer	8.22e-05	0.00188	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—YAP1—head and neck cancer	8.13e-05	0.00186	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—GSTM1—head and neck cancer	8.1e-05	0.00186	CbGpPWpGaD
Zalcitabine—CYP3A5—Biological oxidations—CYP1A1—head and neck cancer	7.79e-05	0.00178	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—NAT2—head and neck cancer	7.73e-05	0.00177	CbGpPWpGaD
Zalcitabine—CYP3A5—Metapathway biotransformation—CYP1A1—head and neck cancer	7.68e-05	0.00176	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	7.63e-05	0.00175	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—UROD—head and neck cancer	6.85e-05	0.00157	CbGpPWpGaD
Zalcitabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	6.82e-05	0.00156	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	5.84e-05	0.00134	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	5.79e-05	0.00133	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	5.76e-05	0.00132	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	5.71e-05	0.00131	CbGpPWpGaD
Zalcitabine—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	5.54e-05	0.00127	CbGpPWpGaD
Zalcitabine—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	5.49e-05	0.00126	CbGpPWpGaD
Zalcitabine—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	5.46e-05	0.00125	CbGpPWpGaD
Zalcitabine—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	5.42e-05	0.00124	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—TYMS—head and neck cancer	4.96e-05	0.00114	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—GSTM1—head and neck cancer	4.9e-05	0.00112	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—TYMS—head and neck cancer	4.88e-05	0.00112	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—UROD—head and neck cancer	4.87e-05	0.00112	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—UROD—head and neck cancer	4.83e-05	0.00111	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—GSTM1—head and neck cancer	4.83e-05	0.00111	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—GPX1—head and neck cancer	4.69e-05	0.00108	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—CYP1A1—head and neck cancer	4.65e-05	0.00106	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—GPX1—head and neck cancer	4.62e-05	0.00106	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—CYP1A1—head and neck cancer	4.57e-05	0.00105	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—NAT2—head and neck cancer	3.94e-05	0.000902	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	3.82e-05	0.000875	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	3.77e-05	0.000863	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	3.75e-05	0.000858	CbGpPWpGaD
Zalcitabine—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	3.62e-05	0.00083	CbGpPWpGaD
Zalcitabine—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	3.57e-05	0.000818	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—DPYD—head and neck cancer	3.45e-05	0.000791	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—YAP1—head and neck cancer	3.27e-05	0.00075	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—UROD—head and neck cancer	3.19e-05	0.00073	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—NAT2—head and neck cancer	2.84e-05	0.000652	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PTGS2—head and neck cancer	2.76e-05	0.000633	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PTGS2—head and neck cancer	2.72e-05	0.000623	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—DPYD—head and neck cancer	2.49e-05	0.000571	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PTEN—head and neck cancer	2.41e-05	0.000552	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PTEN—head and neck cancer	2.37e-05	0.000544	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—YAP1—head and neck cancer	2.37e-05	0.000542	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.13e-05	0.000488	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.11e-05	0.000483	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—NAT2—head and neck cancer	2.02e-05	0.000463	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—NAT2—head and neck cancer	2.01e-05	0.000459	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—TYMS—head and neck cancer	1.97e-05	0.00045	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—GSTM1—head and neck cancer	1.94e-05	0.000445	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—GPX1—head and neck cancer	1.86e-05	0.000426	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—CYP1A1—head and neck cancer	1.84e-05	0.000422	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—DPYD—head and neck cancer	1.77e-05	0.000406	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—DPYD—head and neck cancer	1.76e-05	0.000403	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—PIK3CA—head and neck cancer	1.7e-05	0.000389	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—YAP1—head and neck cancer	1.68e-05	0.000386	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—PIK3CA—head and neck cancer	1.67e-05	0.000383	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—YAP1—head and neck cancer	1.67e-05	0.000382	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—TYMS—head and neck cancer	1.42e-05	0.000326	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—GSTM1—head and neck cancer	1.41e-05	0.000322	CbGpPWpGaD
Zalcitabine—DCK—Metabolism—AKT1—head and neck cancer	1.39e-05	0.000318	CbGpPWpGaD
Zalcitabine—CYP3A43—Metabolism—AKT1—head and neck cancer	1.37e-05	0.000313	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—GPX1—head and neck cancer	1.35e-05	0.000308	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—CYP1A1—head and neck cancer	1.33e-05	0.000305	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—NAT2—head and neck cancer	1.32e-05	0.000303	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.25e-05	0.000287	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—DPYD—head and neck cancer	1.16e-05	0.000266	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—YAP1—head and neck cancer	1.1e-05	0.000252	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PTGS2—head and neck cancer	1.1e-05	0.000251	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.09e-05	0.000251	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—TYMS—head and neck cancer	1.01e-05	0.000232	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—TYMS—head and neck cancer	1e-05	0.00023	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GSTM1—head and neck cancer	9.99e-06	0.000229	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GSTM1—head and neck cancer	9.9e-06	0.000227	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—GPX1—head and neck cancer	9.57e-06	0.000219	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PTEN—head and neck cancer	9.56e-06	0.000219	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—GPX1—head and neck cancer	9.49e-06	0.000217	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—CYP1A1—head and neck cancer	9.47e-06	0.000217	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—CYP1A1—head and neck cancer	9.39e-06	0.000215	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PTGS2—head and neck cancer	7.92e-06	0.000181	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.71e-06	0.000177	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PTEN—head and neck cancer	6.91e-06	0.000158	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—PIK3CA—head and neck cancer	6.74e-06	0.000154	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—TYMS—head and neck cancer	6.61e-06	0.000151	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GSTM1—head and neck cancer	6.53e-06	0.00015	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—GPX1—head and neck cancer	6.26e-06	0.000143	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—CYP1A1—head and neck cancer	6.19e-06	0.000142	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PTGS2—head and neck cancer	5.63e-06	0.000129	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PTGS2—head and neck cancer	5.58e-06	0.000128	CbGpPWpGaD
Zalcitabine—CYP3A7—Metabolism—AKT1—head and neck cancer	5.51e-06	0.000126	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PTEN—head and neck cancer	4.91e-06	0.000113	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—PIK3CA—head and neck cancer	4.87e-06	0.000112	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PTEN—head and neck cancer	4.87e-06	0.000112	CbGpPWpGaD
Zalcitabine—CYP3A5—Metabolism—AKT1—head and neck cancer	3.98e-06	9.12e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PTGS2—head and neck cancer	3.68e-06	8.44e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—PIK3CA—head and neck cancer	3.47e-06	7.94e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—PIK3CA—head and neck cancer	3.44e-06	7.87e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PTEN—head and neck cancer	3.21e-06	7.36e-05	CbGpPWpGaD
Zalcitabine—CYP2D6—Metabolism—AKT1—head and neck cancer	2.83e-06	6.49e-05	CbGpPWpGaD
Zalcitabine—CYP2C9—Metabolism—AKT1—head and neck cancer	2.81e-06	6.43e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—PIK3CA—head and neck cancer	2.27e-06	5.19e-05	CbGpPWpGaD
Zalcitabine—CYP3A4—Metabolism—AKT1—head and neck cancer	1.85e-06	4.24e-05	CbGpPWpGaD
